A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

Lung Cancer

Volumn 82, Issue 1, 2013, Pages 109-114

  Goto, Koichi ^a   Nishio, Makoto ^b   Yamamoto, Noboru ^c   Chikamori, Kenichi ^d   Hida, Toyoaki ^e   Maemondo, Makoto ^f   Katakami, Nobuyuki ^g   Kozuki, Toshiyuki ^h   Yoshioka, Hiroshige ⁱ   Seto, Takashi ^j   Fukuyama, Tamaki ^k   Tamura, Tomohide ^c  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL SANYO HOSPITAL   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f Miyagi Cancer Center   (Japan)

^g INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

ⁱ KURASHIKI CENTRAL HOSPITAL   (Japan)

^j NATIONAL KYUSHU CANCER CENTER   (Japan)

^k CHUGAI PHARMACEUTICAL CO LTD   (Japan)

more..

Author keywords

EGFR testing; Epidermal growth factor receptor (EGFR) mutations; Erlotinib; First line; Japanese patients; Non small cell lung cancer (NSCLC); Phase II

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; DECREASED APPETITE; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; FEASIBILITY STUDY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; JAPANESE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARONYCHIA; PHASE 2 CLINICAL TRIAL; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; RHINOPHARYNGITIS; SIDE EFFECT; STOMATITIS;

EGFR TESTING; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS; ERLOTINIB; FIRST LINE; JAPANESE PATIENTS; NON-SMALL-CELL LUNG CANCER (NSCLC); PHASE II;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84884411444     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.07.003     Document Type: Article

References (12)

1. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
2. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
3. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
4. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
5. Kimura H., Kasahara K., Kawaishi M., Kunitoh H., Tamura T., Holloway B., et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006, 12:3915-3921.
6. Fukuoka M., Wu Y., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V., et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
7. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
8. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
9. Jackman D., Miller V., Cioffredi L.A., Yeap B.Y., Jänne P.A., Riely G.J., et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small-cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009, 15:5267-5273.
10. Kubota K., Nishiwaki Y., Tamura T., Nakagawa K., Matsui K., Watanabe K., et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008, 3:1439-1445.
11. Takahashi T., Yamamoto N., Nukiwa T., Mori K., Tsuboi M., Horai T., et al. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res 2010, 30:557-563.
12. Nakagawa K., Kudoh S., Ohe Y., Johkoh T., Ando M., Yamazaki N., et al. Post-marketing surveillance study of erlotinib in Japanese patients with non-small cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol 2012, 7:1296-1303.